




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 225/08, A61K 31/395, C07D 409/12	A1	(11) International Publication Number: WO 00/20398 (43) International Publication Date: 13 April 2000 (13.04.00)
(21) International Application Number: PCT/CA99/00927 (22) International Filing Date: 5 October 1999 (05.10.99) (30) Priority Data: 60/103,371 7 October 1998 (07.10.98) US (71) Applicant (for all designated States except US): MERCK FROSST CANADA & CO. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): ATKINSON, Joseph, G. [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). LACOMBE, Patrick [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). LABELLE, Marc [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). RUELE, Rejean [CA/CA]; 16711 Trans-Canada Highway, Kirkland, Québec H9H 3L1 (CA). (74) Agents: COTE, France et al.; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montreal, Québec H3A 2Y3 (CA).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>

(54) Title: BIPHENYLENE LACTAMS AS PROSTAGLANDIN RECEPTOR LIGANDS



(II)

(57) Abstract

The present invention relates to biphenylene lactams of Formula (II) which are ligands at the prostaglandin receptors, as well as a method for treating prostaglandin mediated diseases comprising administration to a patient in need of such a treatment of a non-toxic therapeutically effective amount of compound of Formula (II), and the like.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TITLE OF THE INVENTION

BIPHENYLENE LACTAMS AS PROSTAGLANDIN RECEPTOR LIGANDS


BACKGROUND OF THE INVENTION

5 This invention relates to compounds and methods for treating
prostaglandin mediated diseases, certain pharmaceutical compositions
thereof, and the like. More particularly, the compounds of the invention are
structurally different from nonsteroidal anti-inflammatory drugs (NSAIDs)
and opiates, and are antagonists of the pain and inflammatory effects of E-type
10 prostaglandins.

Two review articles describe the characterization and therapeutic
relevance of the prostanoid receptors as well as the most commonly used
selective agonists and antagonists: *Eicosanoids: From Biotechnology to
Therapeutic Applications*, Folco, Samuelsson, Macclouf, and Velo eds, Plenum
15 Press, New York, 1996, chap. 14, 137-154 and *Journal of Lipid Mediators and
Cell Signalling*, 1996, 14, 83-87. An article from *The British Journal of
Pharmacology* (1994, 112, 735-740) suggests that Prostaglandin E₂ (PGE₂)
exerts allodynia through the EP₁ receptor subtype and hyperalgesia through
EP₂ and EP₃ receptors in the mouse spinal cord.

20 Thus, selective prostaglandin ligands, agonists or antagonists,
depending on which prostaglandin E receptor subtype is being considered, will
have anti-inflammatory, antipyretic and analgesic properties similar to a
conventional non-steroidal anti-inflammatory drug and, in addition, will
inhibit hormone-induced uterine contractions and have potential anti-cancer
25 effects, but will have a diminished ability to induce some of the mechanism-
based side effects of NSAIDs which are indiscriminate cyclooxygenase
inhibitors. In particular, such a compound should have a reduced potential
for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced
effect on bleeding times and a lessened ability to induce asthma attacks in
30 aspirin-sensitive asthmatic subjects. In *The American Physiological Society*
(1994, 267, R289-R-294), studies suggest that PGE₂-induced hyperthermia in the

rat is mediated predominantly through the EP₁ receptor. World patent applications WO 96/06822 (March 7, 1996), WO 96/11902 (April 25, 1996) and EP 752421-A1 (January 08, 1997) disclose compounds represented by Formula I as being useful in the treatment of prostaglandin mediated diseases.



wherein:

A is phenyl, naphthyl, 5- or 6-membered heteroaryl;

B is phenyl, 5- or 6-membered heteroaryl or a keto-dihydro ring;

10 D is phenyl, 5- or 6-membered heteroaryl;

R¹ is COOH, (CH₂)_nCOOH, tetrazolyl(alkyl);

R³ is H, alkyl;

Z is an alkylene bridge;


1a is one of the compounds specifically claimed.

SUMMARY OF THE INVENTION

The present invention relates to biphenylene lactams which are ligands at the prostaglandin receptors, as well as a method for treating prostaglandin mediated diseases comprising administration to a patient in need of such a treatment of a non-toxic therapeutically effective amount of compound of Formula II, and the like.

DETAILED DESCRIPTION OF THE INVENTION

An embodiment of the present invention is a compound of structural Formula II:



II

or a pharmaceutically acceptable salt, crystal form, or hydrate thereof, wherein:

A and B are independently unsubstituted, monosubstituted or disubstituted *ortho*-benzenediyl or *ortho*-heteroarylenediyl wherein the substituents are selected from the group consisting of:

- a) halogen,
- b) C₁₋₅ alkyl,
- c) C₁₋₅ alkoxy,
- d) C₁₋₅ alkylthio,
- e) nitro,
- f) CN,
- g) C₁₋₅ fluoroalkyl,
- h) COOR³, and
- i) NR₂³;

X is CH₂CH₂, CH=CH, CH₂Y, YCH₂, CH₂CH₂CH₂, *ortho*-benzenediyl or *ortho*-heteroarylenediyl;

Y is O, S, CF₂, or C=O;

D is unsubstituted, monosubstituted, or disubstituted benzendiyl

5 wherein the substituents are selected from:

- a) halogen,
- b) C₁₋₅ alkyl,
- c) C₁₋₅ alkoxy,
- d) C₁₋₅ alkylthio,
- 10 e) nitro,
- f) CN,
- g) C₁₋₅ fluoroalkyl,
- h) COOR³, and
- i) NR³₂;

15

R is:

- a) C₁₋₆ alkyl,
- b) (CR¹R²)_nO-Ph,
- c) (CR¹R²)_nO-heteroaryl,
- 20 d) O-(CR¹R²)_nPh,
- e) O-(CR¹R²)_nheteroaryl,
- f) NR³-(CR¹R²)_nPh,
- g) NR³-(CR¹R²)_nheteroaryl,
- h) C₂₋₆ alkenyl-Ph,
- 25 i) C₂₋₆ alkenyl-heteroaryl,
- j) (CR¹R²)_nPh, or

k) $(CR^1R^2)_n$ heteroaryl,

wherein Ph or heteroaryl is unsubstituted, monosubstituted or disubstituted with substituents selected from:

- 1) halogen,
- 5 2) C_{1-5} alkyl,
- 3) C_{1-5} alkoxy,
- 4) C_{1-5} alkylthio,
- 5) nitro,
- 6) CN,
- 10 7) C_{1-5} fluoroalkyl,
- 8) $COOR^3$, and
- 9) NR^3_2 ;

n = 0, 1, 2 or 3;

- 15 R^1 and R^2 are independently hydrogen, C_{1-3} alkyl, benzyl, C_{1-3} fluoroalkyl, C_{1-3} alkoxy, or fluorine;
- R^3 is H or C_{1-6} alkyl.

A subembodiment of the invention is the compound of structural Formula II as recited above, wherein:

20

A and B are independently unsubstituted, monosubstituted or disubstituted *ortho*-benzenediyl wherein the substituents are selected from the group consisting of:

- a) halogen,
- 25 b) C_{1-5} alkyl,
- c) C_{1-5} alkoxy,
- d) C_{1-5} alkylthio,

- e) nitro,
- f) CN,
- g) C₁₋₅ fluoroalkyl,
- h) COOR³, and
- 5 i) NR³₂;

X is CH₂CH₂, CH=CH, CH₂Y, YCH₂, CHCH₂CH, *ortho*-benzenediyl or *ortho*-heteroarylenediyl;

- 10 Y is O or S;

D is unsubstituted or monosubstituted benzendiyl wherein the substituents are selected from:

- a) halogen,
- 15 b) C₁₋₃ alkyl,
- c) C₁₋₃ alkoxy,
- d) C₁₋₃ alkylthio,
- e) nitro,
- f) CN,
- 20 g) C₁₋₃ fluoroalkyl,
- h) COOR³, and
- i) NR³₂;

R is:

- 25 a) C₁₋₆ alkyl,
- b) (CR¹R²)_nO-Ph,
- c) O-(CR¹R²)_nPh,

- d) $\text{NR}^3\text{-(CR}^1\text{R}^2)_n\text{Ph}$,
e) $\text{NR}^3\text{-(CR}^1\text{R}^2)_n\text{heteroaryl}$,
f) $\text{C}_{2-6}\text{ alkenyl-Ph}$, or
g) $(\text{CR}^1\text{R}^2)_n\text{Ph}$,
5 wherein Ph or heteroaryl is unsubstituted, monosubstituted or disubstituted with substituents selected from:
- 1) halogen,
 - 2) C_{1-3} alkyl,
 - 3) C_{1-3} alkoxy,
 - 10 4) C_{1-3} alkylthio,
 - 5) nitro,
 - 6) CN,
 - 7) C_{1-3} fluoroalkyl,
 - 8) COOR^3 , and
 - 15 9) NR^3_2 ;

$n = 0, 1, 2 \text{ or } 3$;

R^1 and R^2 are independently hydrogen, C_{1-3} alkyl, C_{1-3} fluoroalkyl, or
20 C_{1-3} alkoxy;

R^3 is H or C_{1-6} alkyl.

A most preferred embodiment of the invention is the
25 compound of structural Formula II above, wherein:

A and B are independently unsubstituted, monosubstituted or disubstituted *ortho*-benzenediyl wherein the substituents are halogen;

X is CH_2CH_2 , $\text{CH}=\text{CH}$, or OCH_2 ;

5

D is benzendiyyl;

R is:

- a) C_{1-3} alkyl,
- 10 b) $(\text{CR}^1\text{R}^2)_n\text{O-Ph}$,
- c) $\text{O-(CR}^1\text{R}^2)_n\text{Ph}$,
- d) $\text{NR}^3\text{-(CR}^1\text{R}^2)_n\text{Ph}$,
- e) $\text{NR}^3\text{-(CR}^1\text{R}^2)_n\text{thienyl}$,
- f) C_{2-3} alkenyl-Ph, or
- 15 g) $(\text{CR}^1\text{R}^2)_n\text{Ph}$,

wherein Ph is unsubstituted or monosubstituted with halogen;

n = 0, 1, 2 or 3;

- 20 R^1 and R^2 are independently hydrogen, C_{1-3} alkyl, C_{1-3} fluoroalkyl, or C_{1-3} alkoxy;

R^3 is H or C_{1-3} alkyl.

- 25 Another embodiment of the present invention is a method for treating or preventing a prostaglandin mediated condition comprising administration to a mammalian patient in need of such a treatment of a non-toxic therapeutically effective amount of a compound

of Formula II above. A preferred prostaglandin mediated condition is inflammation. Yet another embodiment of the invention is a method for treating or preventing a prostaglandin mediated condition in a mammal, comprising the administration of a non-toxic therapeutically effective amount of a compound of Formula II and a nonsteroidal anti-inflammatory drug. Preferred nonsteroidal anti-inflammatory drugs are aspirin, ibuprofen, naproxen, and ketoprofen. Another embodiment of the invention is a method for treating or preventing a prostaglandin mediated condition in a mammal, comprising the administration of a non-toxic therapeutically effective amount of a compound of Formula II as recited in Claim 1 and a cyclooxygenase-2 (COX-2) selective inhibitor. Examples of such COX-2 inhibitors are disclosed in U.S. Patent Nos. 5,474,995; 5,633,272; and 5,466,823; and in WO 96/25405, WO 97/38986, WO 98/03484, WO 97/14691, and WO 95/0051.

Preferred prostaglandin mediated conditions are rheumatic fever, influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), Paget's disease, gout and ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures, immune diseases, autoimmune diseases, diabetic retinopathy, asthma, Alzheimer's disease, eosinophil related disorders, tumor angiogenesis, cytotoxicity due to chemotherapy, glaucoma, and cancer.

Yet another embodiment is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula II or a pharmaceutically acceptable crystal form or hydrate thereof, with or without a nonsteroidal anti-inflammatory. Preferred nonsteroidal anti-inflammatories are aspirin, ibuprofen, naproxen, and ketoprofen. Another subembodiment of the invention is a

pharmaceutical composition comprising a pharmaceutically acceptable carrier, a compound of Formula II, or a pharmaceutically acceptable crystal form or hydrate thereof, and a cyclooxygenase-2 (COX-2) selective inhibitor. Preferred COX-2 inhibitors are those disclosed in U.S. Patent
5 5,474,995, and celecoxib.

The terms alkyl, alkenyl, and alkynyl mean linear, branched, and cyclic structures and combinations thereof. The term "alkyl" includes "cycloalkyl" and "lower alkyl" and extends to cover carbon fragments having up to 20 carbon atoms. Examples of alkyl
10 groups include octyl, nonyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, eicosyl, 3,7-diethyl-2,2-dimethyl-4-propylnonyl, and the like.

"Lower alkyl" includes "lower cycloalkyl" and means alkyl groups of from 1 to 7 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl, pentyl,
15 hexyl, heptyl, and the like.

"Cycloalkyl" includes "lower cycloalkyl" and means a hydrocarbon, containing one or more rings of from 3 to 12 carbon atoms, with the hydrocarbon having up to a total of 20 carbon atoms. Examples of cycloalkyl groups are cyclopropyl, cyclopentyl, cyclo-heptyl,
20 aldamantyl, cyclododecylmethyl, 2-ethyl-1- bicyclo[4.4.0]decyl, and the like.

"Lower cycloalkyl" means a hydrocarbon containing one or more rings of from 3 to 7 carbon atoms, with the hydrocarbon having up to a total of 7 carbon atoms. Examples of lower cycloalkyl groups are
25 cyclopropyl, cyclopropylmethyl, cyclobutyl, 2-cyclopentylethyl, cycloheptyl, bicyclo[2.2.1]hept-2-yl, and the like.

The term "alkenyl" includes "cycloalkenyl" and "lower alkenyl" and means alkenyl groups of 2 to 20 carbon atoms. Examples of alkenyl groups include allyl, 5-decen-1-yl, 2-dodecen-1-yl, and the like.

30 "Lower alkenyl" includes "lower cycloalkenyl" and means alkenyl groups of 2 to 7 carbon atoms. Examples of lower alkenyl groups

include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.

"Cycloalkenyl" includes "lower cycloalkenyl" and means alkenyl groups of 3 to 20 carbon atoms, which include a ring of 3 to 12
5 carbon atoms, and in which the alkenyl double bond may be located anywhere in the structure. Examples of cycloalkenyl groups are cyclopropen-1-yl, cyclohexen-3-yl, 2-vinyladamant-1-yl, 5-methylene-dodec-1-yl, and the like.

"Lower cycloalkenyl" means alkenyl groups of 3 to 7 carbon
10 atoms, which include a ring of 3 to 7 carbon atoms and in which the double bond may be located anywhere in the structure. Examples of lower cycloalkenyl groups are cyclopropen-1-yl, cyclohexen-3-yl, 2-cyclopentylethen-1-yl, and the like.

The term "heteroaryl" as utilized herein, unless specifically
15 defined otherwise, is intended to include the following: a 5 or 6-membered ring substituted with one, two or three heteroatoms selected from O, S, N, and is unsubstituted or substituted with one or two substituents selected from the group consisting of: halogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ alkylthio, nitro, CN, C₁₋₃ fluoroalkyl, COOR³, and NR₂³;
20 any two adjacent substituents can be joined to form a 5-, 6- or 7-membered fused ring said ring containing 1 or 2 oxygen atoms and the remainder carbon atoms, or any two adjacent substituents can be joined together to form a benzo-fused ring. Heteroaryl groups within the scope of this definition include but are not limited to: acridinyl, carbazolyl,
25 cinnolinyl, quinoxalinyl, pyrazolyl, indolyl, benzotriazolyl, furanyl, thienyl, benzothienyl, benzofuranyl, quinolinyl, isoquinolinyl, pyrazinyl, pyridazinyl, pyridinyl, pyrimidinyl, and pyrrolyl which are substituted or unsubstituted as defined above.

The term "Ph" as used herein is intended to mean a phenyl
30 substituent that is unsubstituted or substituted with one or two

substituents selected from the group consisting of: halogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, C₁₋₃ alkylthio, nitro, CN, C₁₋₃ fluoroalkyl, COOR³, and NR³₂; any two adjacent substituents can be joined to form to form a benzo-fused ring. Examples of Ph substituents include but are not limited to phenyl and naphthyl.

The heteroaryl group may be optionally substituted with the substituents listed above at any available carbon atom or nitrogen atom (if present), but compounds bearing certain substituents, directly substituted to a nitrogen may be relatively unstable and are not preferred. The heteroaryl may also be fused to a second 5-, 6-, or 7-membered ring containing one or two oxygens such as: dioxolanyl, dihydrofuranyl, dihydropyranyl, and dioxanyl.

As used herein, the terms "benzenediyl" and "heteroarylenediyl" are intended to mean disubstituted heteroaryl and Ph as defined above. Unless specifically mentioned otherwise, the substitution may be para, meta, or ortho.

It is intended that the definition of any substituent (e.g., R⁶, R¹⁰, etc.) in a particular molecule be independent of its definition elsewhere in the molecule. Thus, -N(R³)₂ represents -NHH, -NHCH₃, -NHC₆H₅, etc.

As used herein, the term "composition" is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

Optical Isomers - Diastereomers - Geometric Isomers

Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such

possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and pharmaceutically acceptable salts thereof.

Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.

Salts

The pharmaceutical compositions of the present invention comprise a compound of Formula II as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including

inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids.

It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula II are meant to also include the pharmaceutically acceptable salts.

Dose Ranges

The magnitude of prophylactic or therapeutic dose of a compound of Formula II will, of course, vary with the nature and the severity of the condition to be treated and with the particular compound of Formula II and its route of administration. It will also vary according to a variety of factors including the age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination and response of the individual patient. In general, the daily dose from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably 0.01 mg to about 10 mg per kg. On the other hand, it may be necessary to use dosages outside these limits in some cases.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 2 g of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

Pharmaceutical Compositions

For the treatment of any of the prostanoid mediated diseases compound II may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term
5 parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the compound of the invention is effective in the
10 treatment of humans.

The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions
15 intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable
20 preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn
25 starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay
30 material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S.

Patent 4,256,108; 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.

Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.

Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents

may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsion. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. In addition, sterile, fixed oils are

conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

5 Compound II may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ambient temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa
10 butter and polyethylene glycols. For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the compound of Formula II are employed. (For purposes of this application, topical application shall include mouth washes and gargles.) Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration
15 enhancer, preservative system, and emollient.

Utilities

 The ability of the compounds of Formula II (i.e., Compound II) to interact with prostaglandin receptors makes them useful for preventing or
20 reversing undesirable symptoms caused by prostaglandins in a mammalian, especially human subject. This mimicking or antagonism of the actions of prostaglandins indicates that the compounds and pharmaceutical compositions thereof are useful to treat, prevent, or ameliorate in mammals and especially in humans: Pain, fever and inflammation of a variety of
25 conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing
30 spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures as well as

immune and autoimmune diseases. In addition, such a compound may inhibit cellular neoplastic transformations and metastatic tumor growth and hence can be used in the treatment of cancer. Compound II may also be of use in the treatment and/or prevention prostaglandin-mediated proliferation disorders such as may occur in diabetic retinopathy and tumor angiogenesis. Compound II will also inhibit prostanoid-induced smooth muscle contraction by antagonizing contractile prostanoids or mimicking relaxing prostanoids and hence may be use in the treatment of dysmenorrhea, premature labor, asthma and eosinophil related disorders. It will also be of use in the treatment of Alzheimer's disease, the treatment of glaucoma, for the prevention of bone loss (treatment of osteoporosis) and for the promotion of bone formation (treatment of fractures) and other bone diseases such as Paget's disease.

By virtue of its prostanoid or prostanoid antagonist activity, Compound II will prove useful as an alternative to conventional non-steroidal anti-inflammatory drugs (NSAID'S) particularly where such non-steroidal anti-inflammatory drugs may be contraindicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems; kidney disease; thrombosis, occlusive vascular diseases; those prior to surgery or taking anti-coagulants. Compound II will also be useful as a cytoprotective agent for patients under chemotherapy. In addition, compounds of Formula II may be combined with conventional nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin, ibuprofen, ketoprofen, and naproxen.

Similarly, compounds of Formula II, will be useful as a partial or complete substitute for conventional NSAIDs in preparations wherein they are presently co-administered with other agents or ingredients. Thus in further aspects, the invention encompasses pharmaceutical compositions for treating prostaglandin mediated diseases as defined above comprising the compound of Formula II as defined above and one or more ingredients such as another pain reliever

including acetaminophen or phenacetin; a potentiator including caffeine; an H₂-antagonist; aluminum or magnesium hydroxide; simethicone; a decongestant including phenylephrine, phenylpropanolamine, pseudophedrine, oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; an antiitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextromethorphan; a diuretic; a sedating or non-sedating antihistamine; a cyclooxygenase-2 (COX-2) inhibitor. Examples of such COX-2 inhibitors are disclosed in U.S. Patent Nos. 5,474,995; 5,633,272; and 5,466,823; and in WO 96/25405, WO 97/38986, WO 98/03484, WO 97/14691, and WO 95/0051. In addition the invention encompasses a method of treating prostaglandin mediated diseases, comprising: administration to a patient in need of such treatment a non-toxic therapeutically effect amount of the compound of Formula II, optionally co-administered with one or more of such ingredients as listed immediately above.

METHODS OF SYNTHESIS

Compounds of the present invention can be prepared according to the following methods. Other synthetic routes will be immediately apparent to those skilled in the art.


Preparation of intermediates:

Biphenyl sulfonamides:


As shown in Scheme I, 2-bromobenzenesulfonyl chloride **III** (purchased from Lancaster) is reacted with *tert*-butylamine. The resulting sulfonamide **IV** is converted, via a palladium-catalyzed coupling with boronic acid **V** (purchased from Omega Chemical Company Inc.) to biphenyl derivative **VI**. When treated with HBr in acetic acid, activation of the hydroxyl group and deprotection occur in the same procedure to afford sulfonamide **VII**. This sulfonamide is a common intermediate used in alkylation reactions with azocinones (dibenzolactams).

10

SCHEME 1



Substituted boronic acids can also be prepared according to
 5 the following scheme:

Synthesis of compounds


10 Azocinones (dibenzolactams):

Tetrahydrodibenz[b,f]azocin-6-one (**VIII**), shown in Scheme 2, is commercially available from Aldrich Chemical Co., Inc., in Milwaukee, WI. The corresponding unsaturated compound **IX** can be prepared (**VIII** can also be prepared in the same manner from

dibenzosuberone) from commercially available dibenzosuberone (**X**) via a two-step sequence (i- oxime formation using hydroxylamine and ii- Beckmann rearrangement on the corresponding tosylate) as shown in Scheme 2.

5

SCHEME 2




10

As depicted in Scheme 3, other dibenzolactam and heteroarylenediyl derivatives can be prepared via a three-step sequence: (I) palladium-catalyzed Heck reaction; (ii) hydrogenation and (iii) cyclization induced by 1-hydroxybenzotriazole hydrate (HOBT), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) and potassium hydride. For example, fluorinated derivatives **XI** and **XII** are prepared from the reaction of styryl derivative **XV** and anilines **XIII** and **XIV**, respectively (both purchased from Lancaster). Heteroaryl starting materials related to **XV** can also be prepared using the Heck reaction on the corresponding heteroaryl bromide and ethylene.

15

SCHEME 3




- 5 Alternatively, compound **VIII** can be converted to **VIIIA** and subsequently to **VIIIB** via a benzylic bromination reaction using N-bromosuccinimide (NBS) outlined in Scheme 4 and described in *J. Org. Chem.* 1972, p. 4907. This intermediate can in turn be transformed to **VIIIC** using standard procedures and **VIIIE** can be obtained from
- 10 **VIIIC** following one of many protocol for carbonyl transposition ($\text{PhCHO, OH}^-/\text{LiAlH}_4, \text{AlCl}_3/\text{O}_3$). These isomers can then each be transformed to the difluoro analog **VIIID** and **VIIIF** by reaction with DAST (diethylaminosulfur trifluoride). The lactams corresponding to products **VIIID** and **VIIIF** can then be obtained using standard
- 15 hydrolytic procedures. Other lactams described herein can be prepared

according to published procedures and/or are commercially available.


SCHEME 4


5



As shown in Scheme 5, dibenzolactam **VIII** was then treated with sodium hydride and sulfonamide **VII** to provide biphenyl derivative **XVI** which serves as a common intermediate for the synthesis of several of the compounds of the present invention. Alternatively, dibenzolactam **VIII** can be replaced by any of the lactams **IX**, **XI** or **XII** and reacted with **VII**. Compound **XVI** can then be transformed to several compounds depending on the choice of the acid chlorides used. For example, treatment of **XVI** with hydrocinnamoyl chloride and Hunig's base in DMF (dimethylformamide) provides acid sulfonamide **XVII**.

SCHEME 5



Preparation of intermediates2-bromo *tert*-butylbenzenesulfonamide IV


5

Tert-butylamine (30 mL, 0.29 mol) was slowly added to a solution of 2-bromobenzenesulfonyl chloride (30 g, 0.11 mol) with mechanical stirring at room temperature. After four hours, the precipitate was filtered and the solvent was evaporated to afford the sulfonamide.

10

¹H nmr (400 MHz, CDCl₃) δ ppm 8.15 (1H, dd, J = 10.5, 2.0 Hz), 7.68 (1H, dd, J = 10.5, 2.0 Hz), 7.40 (1H, m), 7.31 (1H, m), 5.15 (1H, br. s), 1.18 (9H, s).

15 Hydroxymethyl biphenylsulfonamide VI




20

A degassed solution of 2-bromo *tert*-butylbenzenesulfonamide (IV) (15.6 g, 53.5 mmol) and tetrakis(triphenylphosphine)palladium (3.1 g, 2.7 mmol) in dimethoxyethane (270 mL) was stirred at room temperature for 5 minutes. Boronic acid V (purchased from Omega Chemical Company

Inc.) (10 g, 53.5 mmol) and a 2M solution of sodium bicarbonate (53 mL) were then added and the mixture was heated to 90 °C and stirred at this temperature for 24 hours. The mixture was then cooled down and a saturated solution of ammonium chloride (300 mL) and ethyl acetate (300 mL) were added. The separated aqueous layer was extracted with ethyl acetate (3 x 100 mL) and the combined organic layers were dried (MgSO₄ anh.), filtered and evaporated. Flash chromatography of the residue (EtOAc-hexanes 1:1) yielded biphenyl compound VI.

¹H nmr (400 MHz, CDCl₃) δ ppm 8.15 (1H, dd, J = 10.5, 2.0 Hz), 7.50 (6H, m), 7.30 (1H, m), 4.72 (2H, m), 3.61 (1H, m), 1.91 (1H, m), 1.00 (9H, s).

Bromomethyl biphenyl derivative VII



15

Compound VII can be prepared according to the following two alternative methods:

Method 1

20 A solution of hydrobromic acid (48%, 75 mL) was added to a solution of alcohol VI (22.3 g, 69.8 mmol) in acetic acid (75 mL) at room temperature. The mixture was heated to 110 °C and stirred at this temperature for 2.5 hours. After cooling to room temperature, ethanol (100 mL) and toluene (100 mL) were added and the resulting mixture
25 was evaporated under reduced pressure. The residue was dissolved in ethyl acetate and neutralized with saturated aqueous NaHCO₃. The separated aqueous layer was washed with brine, dried (MgSO₄), filtered and evaporated.

Alternatively, compound VII was prepared according to the following two-step procedure.

Method 2

- 5 At 0 °C, carbon tetrabromide (12.5 g, 37.6 mmol) was added to compound VI (10 g, 31.3 mmol) in dichloromethane (100 mL). Bis(diphenylphosphino)ethane (7.5 g, 0.6 mmol) was then added portionwise. The mixture was stirred at 0 °C for 12 hours and it was then poured into dry ether (750 mL), filtered over Celite and evaporated.
- 10 Trifluoroacetic acid (100 mL) was then added and the resulting mixture was evaporated under reduced pressure. The residue was recrystallized from hexanes.

Assays For Determining Biological Activity

- 15 The compound of Formula II can be tested using the following assays to determine their prostanoid antagonist or agonist activity *in vitro* and *in vivo* and their selectivity. The prostaglandin receptors investigated were DP, EP₁, EP₂, EP₃, EP₄, FP, IP and TP.

20 Stable expression of prostanoid receptors in the human embryonic kidney (HEK) 293(ebna) cell line

- Prostanoid receptor cDNAs corresponding to full length coding sequences were subcloned into the appropriate sites of mammalian expression vectors and transfected into HEK 293(ebna)
- 25 cells. HEK 293(ebna) cells expressing the individual cDNAs were grown under selection and individual colonies were isolated after 2-3 weeks of growth using the cloning ring method and subsequently expanded into clonal cell lines.

30 Prostanoid receptor binding assays

HEK 293(ebna) cells are maintained in culture, harvested and membranes are prepared by differential centrifugation, following lysis of the cells in the presence of protease inhibitors, for use in receptor binding assays. Prostanoid receptor binding assays are performed in 10 mM MES/KOH (pH 6.0) (EPs, FP and TP) or 10 mM HEPES/KOH (pH 7.4) (DP and IP), containing 1 mM EDTA, 10 mM divalent cation and the appropriate radioligand. The reaction is initiated by addition of membrane protein. Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations. Non-specific binding is determined in the presence of 1 μ M of the corresponding non-radioactive prostanoid. Incubations are conducted for 60 min at room temperature or 30 °C and terminated by rapid filtration. Specific binding is calculated by subtracting non specific binding from total binding. The residual specific binding at each ligand concentration is calculated and expressed as a function of ligand concentration in order to construct sigmoidal concentration-response curves for determination of ligand affinity.

Prostanoid receptor agonist and antagonist assays

Whole cell second messenger assays measuring stimulation (EP₂, EP₄, DP and IP in HEK 293(ebna) cells) or inhibition (EP₃ in human erythroleukemia (HEL) cells) of intracellular cAMP accumulation or mobilization of intracellular calcium (EP₁, FP and TP in HEK 293(ebna) cells stably transfected with apo-aequorin) are performed to determine whether receptor ligands are agonists or antagonists. For cAMP assays, cells are harvested and resuspended in HBSS containing 25 mM HEPES, pH 7.4. Incubations contain 100 μ M RO-20174 (phosphodiesterase type IV inhibitor, available from Biomol) and, in the case of the EP₃ inhibition assay only, 15 μ M forskolin to stimulate cAMP production. Samples are incubated at 37°C for 10 min, the reaction is terminated and cAMP levels are then measured. For

calcium mobilization assays, cells are charged with the co-factors reduced glutathione and coelenterazine, harvested and resuspended in Ham's F12 medium. Calcium mobilization is measured by monitoring luminescence provoked by calcium binding to the intracellular photoprotein aequorin. Ligands are added in dimethylsulfoxide which is kept constant at 1 % (v/v) in all incubations. For agonists, second messenger responses are expressed as a function of ligand concentration and both EC_{50} values and the maximum response as compared to a prostanoid standard are calculated. For antagonists, the ability of a ligand to inhibit an agonist response is determined by Schild analysis and both K_B and slope values are calculated.

Rat Paw Edema Assay

The method is the same as described in Chan *et al.* (J. Pharmacol. Exp. Ther. 274: 1531-1537, 1995).

LPS-Induced Pyrexia in Conscious Rats

The method is the same as described in Chan *et al.* (J. Pharmacol. Exp. Ther. 274: 1531-1537, 1995).

LPS-Induced Pyrexia in Conscious Squirrel Monkeys

The method is the same as described in Chan *et al.* (Eur. J. Pharmacol. 327: 221- 225, 1997).

Acute Inflammatory Hyperalgesia Induced by Carrageenan in Rats

The method is the same as described in Boyce *et al.* (Neuropharmacology 33: 1609-1611, 1994).

Adjuvant-Induced Arthritis in Rats

Female Lewis rats (body weight ~146-170 g) were weighed, ear marked, and assigned to groups (a negative control group in which

arthritis was not induced, a vehicle control group, a positive control group administered indomethacin at a total daily dose of 1 mg/kg and four groups administered with a test compound at total daily doses of 0.10-3.0 mg/kg) such that the body weights were equivalent within each group. Six groups of 10 rats each were injected into a hind paw with 0.5 mg of *Mycobacterium butyricum* in 0.1 mL of light mineral oil (adjuvant), and a negative control group of 10 rats was not injected with adjuvant. Body weights, contralateral paw volumes (determined by mercury displacement plethysmography) and lateral radiographs (obtained under Ketamine and Xylazine anesthesia) were determined before (day -1) and 21 days following adjuvant injection, and primary paw volumes were determined before (day -1) and on days 4 and 21 following adjuvant injection. The rats were anesthetized with an intramuscular injection of 0.03 - 0.1 mL of a combination of Ketamine (87 mg/kg) and Xylazine (13 mg/kg) for radiographs and injection of adjuvant. The radiographs were made of both hind paws on day 0 and day 21 using the Faxitron (45 kVp, 30 seconds) and Kodak X-OMAT TL film, and were developed in an automatic processor. Radiographs were evaluated for changes in the soft and hard tissues by an investigator who was blinded to experimental treatment. The following radiographic changes were graded numerically according to severity: increased soft issue volume (0-4), narrowing or widening of joint spaces (0-5) subchondral erosion (0-3), periosteal reaction (0-4), osteolysis (0-4) subluxation (0-3), and degenerative joint changes (0-3). Specific criteria were used to establish the numerical grade of severity for each radiographic change. The maximum possible score per foot was 26. A test compound at total daily doses of 0.1, 0.3, 1, and 3 mg/kg/day, indomethacin at a total daily dose of 1 mg/kg/day, or vehicle (0.5% methocel in sterile water) were administered per os b.i.d. beginning post injection of adjuvant and continuing for 21 days. The compounds were prepared weekly, refrigerated in the dark until used, and vortex mixed


immediately prior to administration.

The invention is illustrated in the following non-limiting Examples in which, unless otherwise stated:

- 5 (i) all the end products of the formula II were analyzed by NMR, TLC and mass spectrometry;
- (ii) intermediates were analyzed by NMR and TLC;
- (iii) most compounds were purified by flash chromatography on silica gel, recrystallization and/or swish (suspension in a solvent followed by filtration of the solid) with a solvent such as
10 ether:hexane 1:1;
- (iv) the course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only;
- (v) temperatures are in degrees Celsius.

15 **Table I** illustrates compounds of formula II which are representative of the present invention.

Table 1




EX.	A	B	D	X	R
1	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	CH ₂ CH ₂ Ph
2	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NH(CH ₂) ₂ Ph
3	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NH(CH ₂) ₃ Ph
4	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	OCH ₂ Ph
5	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	CH ₂ OPh
6	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	CH ₂ Ph
7	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	C(CH ₃) ₂ Ph
8	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	CH(CH ₃)Ph
9	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	C(CH ₃) ₂ CH ₂ Ph
10	1,2-Ph	1,2-Ph	1,4-Ph	CH=CH	C(CH ₃) ₂ CH ₂ Ph
11	4-F,1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	C(CH ₃) ₂ CH ₂ Ph
12	4,6-F,1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	C(CH ₃) ₂ CH ₂ Ph
13	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	(S)-C(CF ₃)(OCH ₃)Ph
14	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	(R)-C(CF ₃)(OCH ₃)Ph
15	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NCH ₃ (CH ₂) ₂ Ph
16	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	(S)-NHCH(CH ₃)Ph
17	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NH(CH ₂) ₂ 2-Thiophene
18	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	(E)-CH=CHPh

19	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NH(CH ₂) ₃ CH ₃
20	5-Cl,1,2-Ph	1,2-Ph	1,4-Ph	OCH ₂	NH(CH ₂) ₂ - Thiophene
21	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NHC(CH ₃) ₃
22	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NHCH ₂ Ph
23	1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	<i>o</i> -Cl-Ph
24	1,2-Ph	1,2-Ph	1,4-Ph	OCH ₂	NH(CH ₂) ₂ - Thiophene


EXAMPLE 1

5



¹H nmr (400 MHz, CDCl₃) δ ppm 8.22 (1H, d, J = 10.5), 7.70 (1H, t, J = 10.5 Hz), 7.61 (1H, t, J = 10.5 Hz), 7.35-6.85 (18H, m), 5.70 (1H, m), 5.21 (1H, d, J = 18.0 Hz), 4.90 (1H, d, J = 18.0 Hz), 3.40, 3.25, 2.85 (4H, 3m), 2.97 (2H, t, J = 7.0 Hz), 2.45 (2H, t, J = 7.0 Hz). Elemental analysis calculated for C₃₇H₃₁N₂NaSO₄·2H₂O : C, 67.46; H, 5.36; N, 4.25: found: C, 67.48; H, 4.72; N, 3.57.

EXAMPLE 2




5

^1H nmr (400 MHz, CDCl_3) δ ppm 8.18 (1H, d, $J = 10.5$), 7.66 (1H, t, $J = 10.5$ Hz), 7.59 (1H, t, $J = 10.5$ Hz), 7.35-6.91 (19H), 6.12 (1H, m), 5.30 (1H, d, $J = 18.0$ Hz), 4.85 (1H, d, $J = 18.0$ Hz), 3.30 (3H, m), 2.85 (5H, m). Elemental analysis calculated for $\text{C}_{37}\text{H}_{32}\text{N}_3\text{NaSO}_4 \cdot 2\text{H}_2\text{O}$: C, 65.96; H, 5.39; N, 6.24; found: C, 66.28; H, 5.04; N, 6.23.

10

EXAMPLE 3




15

^1H nmr (400 MHz, CDCl_3) δ ppm 8.18 (1H, d, $J = 10.5$), 7.70 (1H, t, $J = 10.5$ Hz), 7.60 (1H, t, $J = 10.5$ Hz), 7.38-6.95 (19H), 6.15 (1H, m), 5.28 (1H, d, $J = 18.0$ Hz), 4.88 (1H, d, $J = 18.0$ Hz), 3.30-2.50 (8H, m).

1.70 (2H, m). Elemental analysis calculated for $C_{38}H_{34}N_3NaSO_4 \cdot 1.5H_2O$:
C, 67.24; H, 5.49; N, 6.19: found: C, 67.49; H, 5.38; N, 6.14.

EXAMPLE 4


5



¹H nmr (400 MHz, CD₃COCD₃) δ ppm 8.19 (1H, d, J = 10.5 Hz), 7.69 (1H, t, J = 10.5 Hz), 7.59 (1H, t, J = 10.5 Hz), 7.35-6.90 (18H), 5.27
10 (1H, d, J = 10.0 Hz), 5.02 (2H, s), 4.87 (1H, d, J = 10.0 Hz), 3.25 (1H, m),
2.80 (3H, m). Elemental analysis calculated for $C_{38}H_{29}N_2NaSO_5 \cdot 3H_2O$: C,
63.70; H, 5.20; N, 4.13: found: C, 63.51; H, 5.20; N, 4.13.


EXAMPLE 5

15



^1H nmr (400 MHz, CD_3COCD_3) δ ppm 8.21 (1H, d, $J = 10.5$ Hz), 7.75 (1H, t, $J = 10.5$ Hz), 7.68 (1H, t, $J = 10.5$ Hz), 7.38-6.86 (19H), 5.22 (1H, d, $J = 10.0$ Hz), 4.80 (1H, d, $J = 10.0$ Hz), 4.50 (2H, s), 3.22 (1H, m), 2.80 (3H, m). Elemental analysis calculated for $\text{C}_{36}\text{H}_{29}\text{N}_2\text{NaSO}_5 \cdot 1.5\text{H}_2\text{O}$:
 5 C, 66.35; H, 4.95; N, 4.30: found: C, 66.03; H, 4.62; N, 4.20.


EXAMPLE 6



10

^1H nmr (400 MHz, CD_3COCD_3) δ ppm 8.20 (1H, d, $J = 10.5$), 7.70 (1H, t, $J = 10.5$ Hz), 7.60 (1H, t, $J = 10.5$ Hz), 7.35-6.90 (18H), 5.25 (1H, d, $J = 18.0$ Hz), 5.02 (2H, s), 4.95 (1H, d, $J = 18.0$ Hz), 3.50 (2H, s), 3.28 (1H, m), 2.80 (3H, m). Elemental analysis calculated for $\text{C}_{36}\text{H}_{29}\text{N}_2\text{NaSO}_4 \cdot 2\text{H}_2\text{O}$:
 15 : C, 67.07; H, 5.16; N, 4.34: found: C, 67.36; H, 4.85; N, 4.21.

EXAMPLE 7




5

^1H nmr (400 MHz, CDCl_3) δ ppm 8.32 (dd, $J=7.9, 1.5$ Hz, 1H), 7.62 (dt, $J=7.5, 1.4$ Hz, 1H), 7.55 (dt, $J=7.5, 1.5$ Hz, 1H), 7.33-6.86 (m, 19H), 5.33 (d, $J=13.8$ Hz, 1H), 4.68 (d, $J=13.8$ Hz, 1H), 3.22 (m, 1H), 2.77 (m, 1H), 2.62 (m, 2H), 1.47 (s, 6H).

10

EXAMPLE 8




15

^1H nmr (400 MHz, CDCl_3) δ ppm 8.32 (d, $J=8.0$ Hz, 1H), 7.57 (t, $J=7.5$, 1H), 7.50 (t, $J=7.8$ Hz, 1H), 7.30-6.87 (m, 18H), 5.13 (dd, $J=13.9, 2.3$ Hz, 1H), 4.54 (dd, $J=30.9, 14.0$ Hz, 1H), 3.43 (m, 1H), 3.28 (m, 1H), 2.82 (m, 1H), 2.65 (m, 2H), 1.30 (d, $J=7.0$ Hz, 3H).

Elemental analysis calculated for $C_{37}H_{31}N_2NaSO_4 \cdot 1.5H_2O$: C, 68.39; H, 5.27; N, 4.31; S, 4.93: found: C, 68.26; H, 5.22; N, 4.32; S, 4.65.

EXAMPLE 9

5




1H nmr (400 MHz, $CDCl_3$) δ ppm 8.34 (dd, $J=7.8, 1.1$ Hz, 1H), 7.64 (dt, $J=7.5, 1.4$ Hz, 1H), 7.57 (dt, $J=7.6, 1.4$ Hz, 1H), 7.24-6.84 (m, 19H), 5.25 (d, $J=13.0$ Hz, 1H), 4.75 (d, $J=14.0$ Hz, 1H), 3.27 (m, 1H), 2.69 (s, 2H), 2.85-2.60 (m, 3H), 0.99 (s, 3H), 0.98 (s, 3H).

Elemental analysis calculated for $C_{39}H_{35}N_2NaSO_4 \cdot 2H_2O$: C, 68.20; H, 5.72; N, 4.08: found: C, 68.17; H, 5.68; N, 3.95.

15


EXAMPLE 10



¹H nmr (400 MHz, CDCl₃) δ ppm 8.36 (dd, *J* = 7.9, 1.1 Hz, 1H), 7.64 (dt, *J* = 7.5, 1.4 Hz, 1H), 7.57 (dt, *J* = 7.8, 1.4 Hz, 1H), 7.43-6.88 (m, 18H), 6.83 (d, *J* = 11.5 Hz, 1H), 6.51 (d, *J* = 11.5 Hz, 1H), 5.52 (d, *J* = 14.4 Hz, 1H), 4.46 (d, *J* = 14.4 Hz, 1H), 2.69 (m, 2H), 0.98 (s, 3H), 0.96 (s, 3H).
Elemental analysis calculated for C₃₉H₃₃N₂NaSO₄·3H₂O : C, 66.65; H, 5.59; N, 3.98: found: C, 66.80; H, 5.08; N, 4.02.

10


EXAMPLE 11



¹H nmr (400 MHz, CD₃COCD₃) δ ppm 8.35 (dd, *J* = 7.9, 1.2 Hz, 1H), 7.66 (dt, *J* = 7.4, 1.3 Hz, 1H), 7.59 (dt, *J* = 7.8, 1.3 Hz, 1H), 7.37-6.62 (m, 17H), 5.24 (d, *J* = 14.0 Hz, 1H), 4.71 (d, *J* = 14.0 Hz, 1H), 3.27 (m, 1H), 2.70 (s, 2H), 2.85-2.56 (m, 3H), 1.01 (s, 3H), 1.00 (s, 3H). Elemental analysis calculated for C₃₉H₃₄N₂NaFSO₄·2.5H₂O : C, 65.62; H, 5.51; N, 3.92: found: C, 65.37; H, 5.35; N, 3.95.


20

EXAMPLE 12



- 5 ^1H nmr (400 MHz, CD_3COCD_3) δ ppm 8.28 (1H, d, $J = 10.5$), 7.71 (1H, t, $J = 10.5$ Hz), 7.63 (1H, t, $J = 10.5$ Hz), 7.31-6.60 (17H), 5.77 (1H, d, $J = 20.0$ Hz), 4.22 (1H, d, $J = 20.0$ Hz), 3.50 (2H, s), 3.18 (1H, m), 2.85, (1H, m), 2.70 (1H, m), 2.55 (1H, 3m). Elemental analysis calculated for $\text{C}_{39}\text{H}_{33}\text{N}_2\text{NaF}_2\text{SO}_4 \cdot 2 \text{H}_2\text{O}$: C, 64.81; H, 5.16; N, 10 5.26; found: C, 36.1; H, 2.90; N, 1.91.


EXAMPLE 13



¹H nmr (400 MHz, CDCl₃) δ ppm 8.60 (bs, 1H), 8.29 (d, *J* = 8.0 Hz, 1H), 7.62 (t, *J* = 7.5 Hz, 1H), 7.50 (t, *J* = 7.8 Hz, 1H), 7.40-6.86 (m, 18H), 5.33 (dd, *J* = 13.9, 5.9 Hz, 1H), 4.74 (dd, *J* = 13.8, 5.8 Hz, 1H), 3.38 (s, 3H), 3.28 (m, 1H), 2.83 (m, 1H), 2.69 (m, 2H). Elemental analysis calculated for C₃₈H₃₀N₂NaF₃SO₅·2.5H₂O : C, 60.71; H, 4.69; N, 3.73: found: C, 60.63; H, 4.17; N, 3.48.

EXAMPLE 14


10



¹H nmr (400 MHz, CDCl₃) δ ppm 8.45 (bs, 1H), 8.33 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.66 (dt, *J* = 7.5, 1.4 Hz, 1H), 7.57 (dt, *J* = 7.9, 1.4 Hz, 1H), 7.44-6.88 (m, 18H), 5.35 (dd, *J* = 13.9, 4.9 Hz, 1H), 4.78 (dd, *J* = 13.9, 3.8 Hz, 1H), 3.41 (t, *J* = 1.5 Hz, 3H), 3.29 (m, 1H), 2.84 (m, 1H), 2.71 (m, 2H). Elemental analysis calculated for C₃₈H₃₀N₂NaF₃SO₅·2.5H₂O : C, 60.71; H, 4.69; N, 3.73: found: C, 60.43; H, 4.29; N, 3.76.

20

EXAMPLE 15




5

^1H nmr (400 MHz, CD_3COCD_3) δ ppm 8.17 (d, $J=8.0$, 1H), 7.65 (t, $J=7.5$, Hz, 1H), 7.59 (t, $J=7.6$, 1H), 7.38 (d, $J=8.5$ Hz, 2H), 7.35-7.05 (m, 16H), 6.9 (d, $J=8.0$ Hz, 1H), 5.21 (d, $J=15.0$ Hz, 1H), 4.92 (d, $J=15.0$ Hz, 1H), 3.41 (t, $J=7.0$ Hz, 2H), 3.29 (m, 1H), 2.84 (m, 5H).

- 10 Elemental analysis calculated for $\text{C}_{38}\text{H}_{34}\text{N}_3\text{NaSO}_4 \cdot 2.5\text{H}_2\text{O}$: C, 65.50; H, 5.61; N, 6.03; S, 4.60: found: C, 65.64; H, 5.48; N, 5.70 ; S, 4.62.


EXAMPLE 16



15

- ¹H nmr (400 MHz, CD₃COCD₃) δ ppm 8.18 (d, *J* = 8.0 Hz, 1H), 7.67 (t, *J* = 7.5, Hz, 1H), 7.56 (t, *J* = 7.6, 1H), 7.35-6.92 (19H), 6.40, 5.70 (2m, NH rotamers), 5.28 (m, 1H), 4.80 (m, 2H), 3.27 (m, 1H), 2.85 (m, 3H), 1.35 (2d-rotamers, *J* = 7.0 Hz, 3H). Elemental analysis calculated for
- 5 C₃₇H₃₂N₃NaSO₄·5H₂O : C, 61.06; H, 5.81; N, 5.77: found: C, 61.94; H, 5.03; N, 6.03.


EXAMPLE 17



10

- ¹H nmr (400 MHz, CD₃COCD₃) δ ppm 8.19 (d, *J* = 8.0 Hz, 1H), 7.70 (t, *J* = 7.5, Hz, 1H), 7.59 (t, *J* = 7.6, 1H), 7.37-6.70 (17H), 6.18 (br.s, 1H), 5.30 (d, *J* = 10.0 Hz, 1H), 4.78 (d, *J* = 10.0 Hz, 1H), 3.38 (m, 3H), 2.90 (m, 5H). Elemental analysis calculated for C₃₅H₃₀N₃NaS₂O₄·2H₂O : C, 61.84; H, 5.04; N, 6.18; S, 9.43: found: C, 61.59; H, 4.78; N, 6.09; S, 9.51.
- 15


EXAMPLE 18



5

^1H nmr (400 MHz, CD_3COCD_3) δ ppm 8.30 (d, $J = 8.0$ Hz, 1H), 7.71 (t, $J = 7.5$ Hz, 1H), 7.65 (t, $J = 7.6$ Hz, 1H), 7.60-6.90 (19H), 7.08 (d, $J = 15.0$ Hz, 1H), 6.57 (d, $J = 15.0$ Hz, 1H), 5.23 (d, $J = 12.0$ Hz, 1H), 4.91 (d, $J = 12.0$ Hz, 1H), 3.29 (m, 1H), 2.88 (m, 2H), 2.76 (m, 1H). Elemental analysis
 10 calculated for $\text{C}_{37}\text{H}_{29}\text{N}_2\text{NaSO}_4 \cdot 1.5\text{H}_2\text{O}$: C, 68.61; H, 4.98; N, 4.32; S, 4.95:
 found: C, 68.47; H, 4.81; N, 4.37; S, 4.30.

EXAMPLE 19




15

^1H nmr (400 MHz, CDCl_3) δ ppm 8.20 (d, $J = 8.0$ Hz, 1H), 7.70 (t, $J = 7.5$ Hz, 1H), 7.61 (t, $J = 7.6$ Hz, 1H), 7.40-6.92 (13H), 5.31 (d, $J = 10.5$ Hz, 1H), 4.89 (d, $J = 10.5$ Hz, 1H), 3.32-2.70 (m, 6H), 1.30 (m, 4H), 0.85 (t, $J =$

7.0 Hz, 3H). Elemental analysis calculated for $C_{33}H_{32}N_3NaSO_4 \cdot H_2O$: C, 65.22; H, 5.64; N, 6.91; found: C, 65.24; H, 5.64; N, 6.82.

EXAMPLE 20


5



¹H nmr (400 MHz, CD₃COCD₃) 2 rotamers (2:1) δ ppm 8.16, 8.11 (d, *J* = 8.0 Hz, 1H), 7.90-6.70 (17H), 6.88, 6.70 (m, 1H), 5.50, 5.46 (s, 2H), 3.30 (m, 2H), 2.91 (m, 2H). Elemental analysis calculated for C₃₃H₂₅N₃NaS₂ClO₅·2H₂O : C, 56.45; H, 4.16; N, 5.98; found: C, 56.60; H, 3.86; N, 5.68.


EXAMPLE 21

15



^1H nmr (400 MHz, CD_3COCD_3) δ ppm 8.20 (d, $J = 8.0$ Hz, 1H),
 7.79 (t, $J = 8.0$ Hz, 1H), 7.60 (t, $J = 8.0$ Hz, 1H), 7.40-6.95 (m, 13H), 5.92 (s,
 1H), 5.30 (d, $J = 10.0$ Hz), 4.90 (d, $J = 10.0$ Hz), 3.29 (m, 1H), 2.85 (m, 3H).
 Elemental analysis calculated for $\text{C}_{33}\text{H}_{32}\text{N}_3\text{NaSO}_4 \cdot 2\text{H}_2\text{O}$: C, 63.34; H, 5.80;
 5 N, 6.72; found: C, 63.84; H, 5.43; N, 6.50.


EXAMPLE 22



10

^1H nmr (400 MHz, CD_3COCD_3) δ ppm 8.19 (d, $J = 8.0$ Hz, 1H),
 7.79 (t, $J = 8.0$ Hz, 1H), 7.58 (t, $J = 8.0$ Hz, 1H), 7.35-6.90 (m, 18H), 6.53 (br.
 t, $J = 7.0$ Hz, 2H), 5.29 (d, $J = 12.5$ Hz), 4.82 (d, $J = 12.5$ Hz), 4.21 (d, $J = 7.0$
 Hz), 3.25 (m, 1H), 2.80 (m, 3H). Elemental analysis calculated for
 15 $\text{C}_{36}\text{H}_{30}\text{N}_3\text{NaSO}_4 \cdot 1.5\text{H}_2\text{O}$: C, 66.45; H, 5.11; N, 6.46; found: C, 66.47; H, 4.91;
 N, 6.40.

EXAMPLE 23




5

^1H nmr (400 MHz, CD_3COCD_3) δ ppm 8.35 (d, $J = 8.0$ Hz, 1H), 7.75 (t, $J = 8.0$ Hz, 1H), 7.59 (t, $J = 8.0$ Hz, 1H), 7.45-6.91 (m, 18H), 5.21 (d, $J = 10.0$ Hz), 4.87 (d, $J = 10.0$ Hz), 3.21 (m, 1H), 2.80 (m, 3H). Elemental analysis calculated for $\text{C}_{35}\text{H}_{26}\text{N}_2\text{NaClSO}_4 \cdot 2\text{H}_2\text{O}$: C, 63.20; H, 4.55; N, 4.21; found: C, 63.60; H, 4.32; N, 4.13.

10

EXAMPLE 24




15

^1H nmr (400 MHz, CD_3COCD_3) δ ppm 8.61 (br. s, 1H), 8.17 (d, $J = 8.0$ Hz, 1H), 7.88 (d, $J = 8.0$ Hz, 1H), 7.69 (t, $J = 8.0$ Hz, 1H), 7.60-7.20

(m, 16H), 6.89 (m, 1H), 6.80 (m, 1H), 6.03 (br. t., $J = 6.5$ Hz, 1H), 5.45 (s, 2H), 3.30 (q, $J = 6.5$ Hz, 2H), 2.91 (t, $J = 6.5$ Hz, 2H). Elemental analysis calculated for $C_{33}H_{26}N_3NaS_2O_5 \cdot 1.5H_2O$: C, 60.17; H, 4.44; N, 6.38; found: C, 60.42; H, 4.10; N, 6.18.

WHAT IS CLAIMED IS:

1. A compound of structural Formula II:



II

5 or a pharmaceutically acceptable salt, crystal form, or hydrate thereof, wherein:

A and B are independently unsubstituted, monosubstituted or disubstituted *ortho*-benzenediyl or *ortho*-heteroarylenediyl wherein the substituents are selected from the group consisting

10 of:

- a) halogen,
- b) C₁₋₅ alkyl,
- c) C₁₋₅ alkoxy,
- d) C₁₋₅ alkylthio,

15 e) nitro,

f) CN,

g) C₁₋₅ fluoroalkyl,

h) COOR³, and

i) NR³₂;

20 X is CH₂CH₂, CH=CH, CH₂Y, YCH₂, CH₂CH₂CH₂, benzenediyl or heteroarylenediyl;

Y is O, S, CF₂, or C=O;

D is unsubstituted, monosubstituted, or disubstituted benzendiyl wherein the substituents are selected from:

- a) halogen,
 - 5 b) C₁₋₅ alkyl,
 - c) C₁₋₅ alkoxy,
 - d) C₁₋₅ alkylthio,
 - e) nitro,
 - f) CN,
 - 10 g) C₁₋₅ fluoroalkyl,
 - h) COOR³, and
 - i) NR³₂;
- R is:**
- a) C₁₋₆ alkyl,
 - 15 b) (CR¹R²)_nO-Ph,
 - c) (CR¹R²)_nO-heteroaryl,
 - d) O-(CR¹R²)_nPh,
 - e) O-(CR¹R²)_nheteroaryl,
 - f) NR³-(CR¹R²)_nPh,
 - 20 g) NR³-(CR¹R²)_nheteroaryl,
 - h) C₂₋₆ alkenyl-Ph,
 - i) C₂₋₆ alkenyl-heteroaryl,
 - j) (CR¹R²)_nPh, or
 - k) (CR¹R²)_nheteroaryl,

wherein Ph or heteroaryl is unsubstituted, monosubstituted or disubstituted with substituents selected from:

- 1) halogen,
- 2) C₁₋₅ alkyl,
- 5 3) C₁₋₅ alkoxy,
- 4) C₁₋₅ alkylthio,
- 5) nitro,
- 6) CN,
- 7) C₁₋₅ fluoroalkyl,
- 10 8) COOR³, and
- 9) NR³₂;

n = 0, 1, 2 or 3;

R¹ and R² are independently hydrogen, C₁₋₃ alkyl, benzyl, C₁₋₃ fluoroalkyl, C₁₋₃ alkoxy, or fluorine;

R³ is H or C₁₋₆ alkyl.

2. The compound of structural Formula II as recited in Claim 1, wherein:
A and B are independently unsubstituted, monosubstituted or disubstituted *ortho*-benzenediyl wherein the substituents are selected from the group consisting of:

- a) halogen,
- 25 b) C₁₋₅ alkyl,
- c) C₁₋₅ alkoxy,

- d) C₁₋₅ alkylthio,
- e) nitro,
- f) CN,
- g) C₁₋₅ fluoroalkyl,
- 5 h) COOR³, and
- i) NR³₂;

X is CH₂CH₂, CH=CH, CH₂Y, YCH₂, CHCH₂CH, benzenediyl or heteroarylenediyl;

10

Y is O or S;

D is unsubstituted or monosubstituted benzendiyl wherein the substituents are selected from:

- 15 a) halogen,
- b) C₁₋₃ alkyl,
- c) C₁₋₃ alkoxy,
- d) C₁₋₃ alkylthio,
- e) nitro,
- 20 f) CN,
- g) C₁₋₃ fluoroalkyl,
- h) COOR³, and
- i) NR³₂;

R is:

- 25 a) C₁₋₆ alkyl,
- b) (CR¹R²)_nO-Ph,

- c) $O-(CR^1R^2)_nPh$,
 - d) $NR^3-(CR^1R^2)_nPh$,
 - e) $NR^3-(CR^1R^2)_nheteroaryl$,
 - f) C₂₋₆ alkenyl-Ph, or
 - 5 g) $(CR^1R^2)_nPh$,
- wherein Ph or heteroaryl is unsubstituted, monosubstituted or disubstituted with substituents selected from:
- 1) halogen,
 - 2) C₁₋₃ alkyl,
 - 10 3) C₁₋₃ alkoxy,
 - 4) C₁₋₃ alkylthio,
 - 5) nitro,
 - 6) CN,
 - 7) C₁₋₃ fluoroalkyl,
 - 15 8) COOR³, and
 - 9) NR³₂;

$n = 0, 1, 2 \text{ or } 3$;

- 20 R¹ and R² are independently hydrogen, C₁₋₃ alkyl, C₁₋₃ fluoroalkyl, or C₁₋₃ alkoxy;
- R³ is H or C₁₋₆ alkyl.

- 3. The compound of structural Formula II as
- 25 recited in Claim 1, wherein:

A and B are independently unsubstituted, monosubstituted or disubstituted *ortho*-benzenediyl wherein the substituents are halogen;

- 5 X is CH_2CH_2 , $\text{CH}=\text{CH}$, or OCH_2 ;
D is benzendiyyl;
R is:
- a) C_{1-3} alkyl,
 - b) $(\text{CR}^1\text{R}^2)_n\text{O-Ph}$,
 - 10 c) $\text{O}-(\text{CR}^1\text{R}^2)_n\text{Ph}$,
 - d) $\text{NR}^3-(\text{CR}^1\text{R}^2)_n\text{Ph}$,
 - e) $\text{NR}^3-(\text{CR}^1\text{R}^2)_n\text{thienyl}$,
 - f) C_{2-3} alkenyl-Ph, or
 - g) $(\text{CR}^1\text{R}^2)_n\text{Ph}$,
- 15 wherein Ph is unsubstituted or monosubstituted with halogen;
 $n = 0, 1, 2$ or 3 ;
 R^1 and R^2 are independently hydrogen, C_{1-3} alkyl, C_{1-3} fluoroalkyl, or C_{1-3} alkoxy;
- 20 R^3 is H or C_{1-3} alkyl.

4. A method for treating or preventing a prostaglandin mediated condition comprising administering to a mammalian patient

in need of such a treatment of an therapeutically effective amount of a compound as recited in Claim 1.

5. The method of Claim 4 wherein the prostaglandin mediated condition is inflammation.

5 6. A method for treating or preventing a prostaglandin mediated condition in a mammal, comprising administering a therapeutically effective amount of a compound of Formula II as recited in Claim 1 and a nonsteroidal anti-inflammatory drug selected from the group consisting of aspirin,
10 ibuprofen, naproxen, and ketoprofen.

7. A method for treating or preventing a prostaglandin mediated condition in a mammal, comprising administering a therapeutically effective amount of a compound
15 of Formula II as recited in Claim 1 and a cyclooxygenase-2 (COX-2) selective inhibitor.

8. The method of Claim 4 wherein the condition is selected from the group consisting of rheumatic fever, influenza
20 or other viral infections, common cold, low back and neck pain, skeletal pain, post-partum pain, dysmenorrhea, headache, migraine, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), Paget's disease, gout and
25 ankylosing spondylitis, bursitis, burns including radiation and corrosive chemical injuries, sunburns, pain following surgical and dental procedures, immune diseases, autoimmune diseases, diabetic retinopathy, asthma, Alzheimer's disease, eosinophil related disorders, tumor angiogenesis, cytotoxicity due to
30 chemotherapy, glaucoma, and cancer.

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Formula II, as recited in any of Claims 1 to 3, or a pharmaceutically acceptable crystal form or hydrate thereof.

5

10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, a compound of Formula II, as recited in any of Claims 1 to 3, or a pharmaceutically acceptable crystal form or hydrate thereof, and a nonsteroidal anti-inflammatory.

10

11. The pharmaceutical composition of Claim 10, wherein the nonsteroidal anti-inflammatory is selected from the group consisting of aspirin, ibuprofen, naproxen, and ketoprofen.

15

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, a compound of Formula II, as recited in any of Claims 1 to 3, or a pharmaceutically acceptable crystal form or hydrate thereof, and a cyclooxygenase-2 (COX-2) selective inhibitor.

20

13. A pharmaceutical composition made by combining the compound of any of Claims 1 to 3 and a pharmaceutically acceptable carrier.

14. A process for making a pharmaceutical composition comprising combining a compound of any of Claims 1 to 3 and a pharmaceutically acceptable carrier.

25

15. A method of treating or preventing a prostaglandin mediated condition in a mammalian patient, comprising administering to such patient an amount of a prostaglandin ligand and a COX-2 selective inhibitor in an amount which is effective to treat or prevent said prostaglandin mediated condition.

30

16. The compound as recited in Claim 1, wherein the substituents are defined as:

35

A	B	D	X	R
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	CH ₂ CH ₂ Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NH(CH ₂) ₂ Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NH(CH ₂) ₃ Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	OCH ₂ Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	CH ₂ OPh
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	CH ₂ Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	C(CH ₃) ₂ Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	CH(CH ₃)Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	C(CH ₃) ₂ CH ₂ Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH=CH	C(CH ₃) ₂ CH ₂ Ph
4-F,1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	C(CH ₃) ₂ CH ₂ Ph
4,6-F,1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	C(CH ₃) ₂ CH ₂ Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	(S)-C(CF ₃)(OCH ₃)Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	(R)-C(CF ₃)(OCH ₃)Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NCH ₃ (CH ₂) ₂ Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	(S)-NHCH(CH ₃)Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NH(CH ₂) ₂ 2-Thiophene
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	(E)-CH=CHPh
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NH(CH ₂) ₃ CH ₃
5-Cl,1,2-Ph	1,2-Ph	1,4-Ph	OCH ₂	NH(CH ₂) ₂ 2-Thiophene
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NHC(CH ₃) ₃
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	NHCH ₂ Ph
1,2-Ph	1,2-Ph	1,4-Ph	CH ₂ CH ₂	o-Cl-Ph
1,2-Ph	1,2-Ph	1,4-Ph	OCH ₂	NH(CH ₂) ₂ 2-Thiophene

17. Use of a compound, or a pharmaceutically acceptable salt, crystal form, or hydrate thereof as defined in any one of Claims 1 to 3, in the manufacture of a medicament for the treatment or prevention of a prostaglandin mediated condition in
5 a mammalian patient.

18. The use of Claim 17, wherein the prostaglandin mediated condition is inflammation.

10 19. A prostaglandin receptor ligand composition comprising an acceptable ligand-binding amount of a compound of Formula II, or a pharmaceutically acceptable salt, crystal form, or a hydrate thereof as defined in any of Claims 1 to 3, in association with a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

Int'l. Application No.
PCT/CA 99/00927

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D225/08 A61K31/395 C07D409/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 480 641 A (IMPERIAL CHEMICAL INDUSTRIES PLC) 15 April 1992 (1992-04-15) page 2, line 30 - line 34; claim 1	1, 17
A	EP 0 752 421 A (ZENECA LTD.) 8 January 1997 (1997-01-08) cited in the application page 3, line 1 - line 13; claim 1	1, 17

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"a" document member of the same patent family

Date of the actual completion of the international search

23 December 1999

Date of mailing of the international search report

11/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3018

Authorized officer

Van Bijlen, H

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 99/ 00927

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 4-8 and 15
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 4-8 and 15
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/CA 99/00927

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 480641	A	15-04-1992	AT 120737 T	15-04-1995
			AU 645837 B	27-01-1994
			AU 8376391 A	09-04-1992
			CA 2051830 A	09-04-1992
			DE 69108665 D	11-05-1995
			DE 69108665 T	17-08-1995
			FI 914476 A	09-04-1992
			JP 4288064 A	13-10-1992
			PT 99170 A	30-09-1992
			US 5189033 A	23-02-1993
EP 752421	A	08-01-1997	JP 9040607 A	10-02-1997
			US 5834468 A	10-11-1998